Update on the Management of High-Risk Penetrating Keratoplasty
Authors:
- 2 February 2017
- journal article
- research article
- Published by Springer Nature in Current Ophthalmology Reports
- Vol. 5 (1) , 38-48
Abstract
Purpose of Review In this article, we review the indications and latest management of high-risk penetrating keratoplasty. Recent Findings Despite the immune privilege status of the cornea, immune-mediated graft rejection still remains the leading cause of corneal graft failure. This is particularly a problem in the high-risk graft recipients, namely patients with previous graft failure due to rejection and those with inflamed and vascularized corneal beds. A number of strategies including both local and systemic immunosuppression are currently used to increase the success rate of high-risk corneal grafts. Moreover, in cases of limbal stem cell deficiency, limbal stem cell transplantation is employed. Summary Corticosteroids are still the top medication for prevention and treatment in cases of corneal graft rejection. Single and combined administration of immunosuppressive agents, e.g., tacrolimus, cyclosporine, and mycophenolate are promising adjunctive therapies for prolonging graft survival. In the future, cellular and molecular therapies should allow us to achieve immunologic tolerance even in high-risk grafts.Keywords
This publication has 98 references indexed in Scilit:
- Long-term Rejection Incidence and Reversibility After Penetrating and Lamellar KeratoplastyAmerican Journal of Ophthalmology, 2013
- Long-term Results of Deep Anterior Lamellar versus Penetrating KeratoplastyOphthalmology, 2012
- Graft failure IV. Immunologic mechanisms of corneal transplant rejectionInternational Ophthalmology, 2007
- Deletion of the Chemokine Receptor CCR1 Prolongs Corneal Allograft SurvivalInvestigative Ophthalmology & Visual Science, 2007
- Corneal Antigen-Presenting Cells2007
- Current Systemic Immunosuppressive Strategies in Penetrating Keratoplasty2006
- Draining Lymph Nodes of Corneal Transplant Hosts Exhibit Evidence for Donor Major Histocompatibility Complex (MHC) Class II–positive Dendritic Cells Derived from MHC Class II–negative GraftsJournal of Experimental Medicine, 2002
- Identification of Androgen Receptors in Rabbit Lacrimal Gland by Immunohistochemsitry2002
- Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eyeEye, 1995
- The Collaborative Corneal Transplantation Studies (CCTS)Archives of Ophthalmology (1950), 1992